Brain PERfusion Evaluation by Contrast-Enhanced UltraSound
Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · May 29, 2023
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
**Trial Summary: Brain Perfusion Evaluation by Contrast-Enhanced Ultrasound**
This clinical trial is exploring how well contrast-enhanced ultrasound (a special imaging technique) can assess blood flow in the brain after serious injuries, such as strokes or bleeding. The main goal is to see if this method can help doctors identify areas of the brain that aren’t getting enough blood—known as hypoperfusion—as well as compare its findings with other standard tests used to monitor brain health.
To participate in this study, individuals must be at least 18 years old and currently in the intensive care unit with a confirmed acute brain injury, as seen on a CT or MRI scan. Participants will need to give their consent, or have a family member provide it on their behalf. It’s important to note that this trial is not open to pregnant individuals or those with certain medical conditions that might make the ultrasound unsafe. If eligible, participants can expect to undergo a contrast ultrasound, which is a straightforward procedure that helps doctors gain valuable insights into their brain's condition.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥18
- • Intensive care unit admission for acute brain injury
- • Proven acute brain injury by CT and/or MRI
- • Requiring a contrast ultrasound imaging
- • Informed consent of patient or relative
- Exclusion Criteria:
- • Pregnancy
- • Not sufficient temporal window
- • Contraindications to Sonovue ® : acute coronary syndromes, severe ischemic heart disease (requiring revascularization), pulmonary arterial hypertension \> 90 mmHg, right-left shunt, ARDS, dobutamine's use, known allergy or adverse reaction to Sonovue®
- • Patient on State Medical Assistance
About Assistance Publique Hôpitaux De Paris
Assistance Publique - Hôpitaux de Paris (AP-HP) is a leading public hospital system in France, renowned for its commitment to healthcare excellence and innovative medical research. As a prominent clinical trial sponsor, AP-HP plays a pivotal role in advancing medical knowledge and improving patient care through rigorous scientific investigations across a wide range of therapeutic areas. With a focus on collaboration and interdisciplinary approaches, AP-HP leverages its extensive network of hospitals and expert clinicians to facilitate high-quality clinical trials that adhere to the highest ethical and regulatory standards, ultimately aiming to translate research findings into tangible health benefits for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Paris, , France
Patients applied
Trial Officials
Romain BARTHELEMY, MD
Principal Investigator
AP-HP Lariboisière Hospital, Department of Anaesthesia and Intensive Care
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported